Skip to Content

Zerbaxa Approval History

FDA Approved: Yes (First approved December 19, 2014)
Brand name: Zerbaxa
Generic name: ceftolozane and tazobactam
Dosage form: Injection
Company: Cubist Pharmaceuticals, Inc.
Treatment for: Intraabdominal Infection, Urinary Tract Infection, Pneumonia

Zerbaxa (ceftolozane and tazobactam) is a cephalosporin and beta-lactamase inhibitor combination for the treatment of:

  • complicated intra-abdominal Infections (cIAI), used in combination with metronidazole
  • complicated urinary tract infections (cUTI), including pyelonephritis
  • hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

Development History and FDA Approval Process for Zerbaxa

DateArticle
Jun  3, 2019Approval FDA Approves Zerbaxa (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Dec 19, 2014Approval FDA Approves Zerbaxa (ceftolozane/tazobactam) for Complicated Intra-Abdominal/Urinary Tract Infections
Apr 23, 2014Cubist Announces Submission of NDA for Investigational Antibiotic Ceftolozane/tazobactam

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide